Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)B-cell acute lymphoblastic leukemia, B-cell chronic lymphocytic leukemia, B-cell neoplasm, Burkitt lymphoma, Chronic Disease, DNA Virus Infections, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Tumor Virus Infections, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma, viral infectious diseaseRecruitingPhase 12026-09-08NCT03666000

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
Imugene Limited3

15 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Barwon Health - Andrew Love Cancer CentreGeelongAustralia1
Baylor University Medical CenterDallasUnited States87
Columbia University Irving Medical Center/New York Presbyterian HospitalNew YorkUnited States10
H. Lee Moffitt Cancer CenterTampaUnited States13
Lifespan Cancer Institute at Rhode Island HospitalProvidenceUnited States1
Liverpool HospitalLiverpoolAustralia66
Medical College of WisconsinMilwaukeeUnited States483
Northside Hospital Cancer InstituteAtlantaUnited States3
Royal Adelaide HospitalAdelaideAustralia132
Royal Prince Alfred HospitalCamperdownAustralia83
St Vincent's Hospital MelbourneFitzroyAustralia27
Tufts Medical CenterBostonUnited States238
University of MarylandBaltimoreUnited States86
University of MinnesotaMinneapolisUnited States325
Winship Cancer Institute Emory UniversityAtlantaUnited States11